Meticulous Research^®—a leading global market research company, published a research report titled, ‘Europe Cancer Diagnostic Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]), Cancer Type (Breast, Lung, Colon, Prostate), End User (Hospital, Imaging Center, Pharmaceutical)–Global Forecast to 2031.’

According to this latest publication from Meticulous Research®, cancer is still one of the toughest health issues in Europe, and diagnostics are right at the center of the fight. The Europe Cancer Diagnostics Market could be worth about $12.21 billion by 2031, growing at roughly 5.6% CAGR. That number does not just come from the rise in cancer cases it also reflects stronger government support for early cancer diagnosis and a shift toward better tools for oncology testing. Hospitals and labs are investing more in cancer imaging and molecular approaches. Some of the fastest growth is in leukemia diagnostics, where precision testing is becoming a bigger part of treatment decisions. At the same time, awareness programs have pushed more people to get cancer testing earlier, which naturally feeds into demand. But the market picture is not all smooth. Imaging systems cost a fortune, and not every clinic can afford them. There is also a shortage of trained professionals, and screening programs are not consistent across all countries. In some places, access is far better than in others. Even with those issues, the overall trend points forward new technology, better funding, and the push for personalized medicine are likely to keep this market moving up.

Key Players:

The key players operating in Europe cancer diagnostics market are F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic, Inc. (U.S.).

Europe Cancer Diagnostics Market: Future Outlook

The Europe cancer diagnostics market is segmented by product (In vitro diagnostics [instruments {polymerase chain reaction (PCR), microarray, immunoassay, sequencers, and other instruments}, consumables {kits & assays and reagents}, software & services], diagnostic imaging [instruments {computed tomography (CT), magnetic resonance imaging (MRI), mammography, ultrasound, and other instruments}, consumables {syringes and injectors, contrast delivery systems, phantoms, skin markers, contrast agents, and other consumables}, software & services]), cancer type (breast cancer, lung cancer, colorectal cancer, prostate cancer, other cancer types), end user (hospitals & diagnostic laboratories, diagnostic imaging centers, pharmaceutical & biotechnology companies, academic & research institutes) and geography. The study also evaluates industry competitors and analyzes the market at country levels.

In Vitro Diagnostics Outpaces Imaging in Europe’s Cancer Diagnostics Market

When you break the Europe Cancer Diagnostics Market down by product, two main categories stand out: in vitro diagnostics (IVD) and diagnostic imaging. Of these, IVD is set to grow the fastest between 2024 and 2031. The reasons are not hard to see. Sequencing costs have dropped sharply, precision oncology testing is gaining traction, and European health programs are encouraging wider use of molecular tools. Companies are also competing aggressively with new product launches, which keeps pushing the segment forward. A recent example is Roche’s LightCycler PRO System, introduced in November 2023. This next-generation qPCR platform is designed to support both cancer diagnostics and infectious disease testing. For healthcare providers, it offers a way to meet rising clinical needs while also addressing broader public health issues. While cancer imaging will remain critical for detection, the momentum is clearly shifting toward IVD especially in specialized areas such as leukemia diagnostics, where molecular methods are becoming standard practice.

Breast Cancer Segment Holds Largest Share of Europe Cancer Diagnostics Market

In 2024, breast cancer is still the top segment in the Europe Cancer Diagnostics Market. Cases are rising across the region, and governments keep investing in awareness and screening. Spending on cancer diagnostics is climbing as health systems focus more on early detection and better treatment. Back in October 2023, Galderma SA launched its “Facing Breast Cancer Together” campaign with the National Breast Cancer Foundation (NBCF). The goal was straightforward: more education, more support, and stronger promotion of early oncology testing. Moves like this keep breast cancer in the spotlight and drive momentum in this area of cancer testing. Other cancers matter too. Cancer imaging is becoming central to detecting lung, colorectal, and prostate cancers. New molecular tools are also helping in leukemia diagnostics. Together, these advances show that Europe’s approach to cancer testing is broadening, even if breast cancer holds the largest share right now.

Hospital-Based Cancer Testing Expands with Advanced Imaging and Diagnostics

Hospitals and diagnostic labs take the lead in the Europe Cancer Diagnostics Market in 2024. Most patients still go through these facilities first, since they offer both the staff and the equipment needed for reliable cancer testing. Insurance coverage and well-equipped rooms give them an edge over smaller providers, while new labs are opening across Europe to handle growing demand. The rise of precision medicine has only strengthened their role. Instead of broad treatments, doctors now rely on targeted oncology testing. Blood or tissue samples are analyzed to find biomarkers, which helps in choosing the right therapy and tracking disease progress. These methods are especially important in areas like leukemia diagnostics, where continuous monitoring can change patient outcomes. Hospitals and labs remain central to cancer imaging and diagnostic services. With more investment flowing into precision oncology, they are expected to stay the backbone of Europe’s cancer diagnostics ecosystem.

Growth Drivers of Cancer Diagnostics and Oncology Testing in Europe

In Europe, cancer diagnostics are tracked across Germany, France, the U.K., Italy, Spain, Switzerland, the Netherlands, and other markets. Germany is expected to come out ahead in 2024. A mix of reasons explains this. The country has seen more cases of hereditary cancer, and people are increasingly aware of the value of early testing. Public health programs also play a role, especially with support for newborn screening and genetic risk assessments. On top of that, Germany hosts several leading companies offering everything from advanced cancer imaging to routine cancer testing and highly focused areas such as leukemia diagnostics. All of this gives Germany a strong position in the Europe Cancer Diagnostics Market, making it a central hub for innovation in oncology testing.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5787

Key questions answered in the report:

Which factors are driving the adoption of oncology testing and early cancer diagnostics across Europe?

How are governments influencing demand through cancer awareness and screening programs?

What impact have falling sequencing costs had on the adoption of molecular and precision testing?

Which recent product launches (e.g., Roche’s LightCycler PRO System) are influencing market competition?

Why does breast cancer remain the largest segment in Europe’s cancer diagnostics market?

How are campaigns and awareness programs driving demand for oncology testing in breast cancer?

Why do hospitals and diagnostic labs dominate cancer testing services in Europe?

What makes Germany the largest market in Europe for cancer diagnostics?

Who are the key players in the European market, and what are their core strengths?

How are global giants like Roche, Siemens Healthineers, and Thermo Fisher competing with local firms?

Contact Us:
Meticulous Research^®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research